Sterol regulatory element-binding proteins (SREBPs) are
transcription factors that regulate
enzymes required for
cholesterol and
fatty acid synthesis. Expression of SREBP-1 is enhanced by
insulin; however, the actual
insulin-signaling cascades employed are yet unclear. We determined the roles of the
phosphatidylinositol (
PI) 3-kinase and
mitogen-activated
protein (MAP)
kinase-dependent pathways in the effect of mediating
insulin on SREBP-1 in L-6 skeletal muscle cells and 3T3 L1 adipocytes, using
wortmannin or
LY294002 to inhibit the
PI 3-kinase pathway, and
PD98059 to inhibit the MAP
kinase-dependent pathway. In myocytes,
insulin increased SREBP-1
protein in a dose-dependent manner. 1 and 10 nm
insulin significantly increased expression of total cellular SREBP-1
protein at 24 and 48 h, nuclear SREBP-1
protein at 24 h, and
SREBP-1a mRNA at 24 h. Although
wortmannin and
LY294002 had no effect on this aspect of
insulin action,
PD98059 completely blocked each of these responses. Transfection of a dominant negative mutant of Ras similarly blocked the
insulin effect on SREBP-1. In contrast, in adipocytes, the
insulin effect on SREBP-1 was mediated via the
PI 3-kinase and not the MAP
kinase pathway. In conclusion, although
insulin increases skeletal muscle SREBP-1 expression in a dose-dependent fashion via the MAP
kinase-dependent signaling pathway,
insulin action on adipocyte SREBP-1 is mediated via the
PI 3-kinase signaling pathway. In the state of
insulin resistance, characterized by selective inhibition of the
PI 3-kinase pathway, the usual stimulation of lipogenesis by
insulin in adipocytes may be inhibited, whereas intramyocellular lipogenesis via the MAP
kinase pathway of
insulin may continue unabated.